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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effects of nasal saline irrigation in patients with allergic rhinitis.
B A C K G R O U N D
Description of the condition
According to the Allergic Rhinitis and its Impact on Asthma
(ARIA) guidelines (ARIA 2008), allergic rhinitis is defined clini-
cally by nasal hypersensitivity symptoms induced by an immuno-
logically mediated (most often IgE-dependent) inflammation of
the nasal mucous membranes after exposure to an offending aller-
gen. Common allergic triggers include house dust mites, pollens
(from trees, grasses, shrubs and weeds), animal dander or fungi,
which occur naturally in the environment. In addition, allergic
rhinitis can be caused by triggers to which a person is exposed in
the course of their work (occupational exposure). These may in-
clude vegetable proteins, enzymes and chemicals (BSACI 2008).
Symptoms of allergic rhinitis may include nasal obstruction
(blockage or congestion), rhinorrhoea (which can be anterior lead-
ing tonasal discharge, or posterior leading to post-nasal drip), nasal
itching and sneezing (ARIA 2008). In addition to nasal symptoms,
some patients with allergic rhinitis also report ear symptoms such
as pain, pressure or feeling of fullness; however, aural symptoms
have also been reported as an adverse effect of nasal saline irrigation
(Chusakul 2013). There is some evidence that people with allergic
rhinitis may experience decreased quality of life due to issues such
as loss of sleep, secondary daytime fatigue, impaired school and
work performance, decreased cognitive functioning and decreased
long-term productivity (Schoenwetter 2004).
Allergic rhinitis is commonly classified into ’intermittent’ and ’per-
sistent’ disease. Intermittent allergic rhinitis is diagnosed when
symptoms are present for less than four days per week or for
less than four weeks. Persistent allergic rhinitis is diagnosed when
symptoms are present more frequently than four days per week
and for at least four consecutive weeks (ARIA 2008). The presence
of intermittent or persistent disease may be related to the type of
allergic triggers for allergic rhinitis, for example intermittent aller-
gic rhinitis may be linked to the release of a certain type of tree
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pollen (such as elm tree pollen) occurring once a year for a period
of a few weeks.
Prior to 2008, allergic rhinitis was classified into ’seasonal’, ’peren-
nial’ and ’occupational’, based on the time of exposure. Seasonal
allergic rhinitis was used to define mainly ’outdoor’ allergens such
as tree pollens, which were not present consistently throughout
the year, whereas the term ’perennial’ allergic rhinitis was used
for ’indoor’ allergens where exposure was thought to be consis-
tent throughout the year. The ARIA 2008 guidelines attempted to
make the classification more useful in the real world by introduc-
ing the terms ’intermittent’ and ’persistent’ to classify the disease.
The previous classification had been felt to be inadequate as it was
noted that in certain situations a seasonal allergen may occur year
round (e.g. grass pollen allergy in Southern California) or symp-
toms of perennial allergy may not always be present all year round
(e.g. in the Mediterranean area where levels of house dust mite
allergen are low in the summer). Thus the change to intermittent
and persistent was made (ARIA 2008).
The ARIA guidelines further classify allergic rhinitis into ’mild’
and ’moderate/severe’ depending on the person’s severity of symp-
toms and the impact of the condition on their quality of life.
Moderate/severe allergic rhinitis is diagnosed when one or more
of the following items are present: sleep disturbance; impairment
of daily activities, leisure or sport; impairment of school or work;
or troublesome symptoms (ARIA 2008).
The diagnosis of allergic rhinitis is based upon clinical symptoms
combined with laboratory studies demonstrating the presence of
allergen-specific IgE in the skin (skin prick test) or blood (serum
IgE). A review of epidemiological studies estimated that 10% to
15% of adults have allergic rhinitis based on both the presence of
symptoms and a positive skin prick test (Mims 2014). However,
the number is higher when people reporting either just symptoms
(up to 34%) or a positive skin prick test (up to 53.9%, testing 10
allergens) are considered (Mims 2014). There are a wide range of
estimates for the prevalence of allergic rhinitis in children (10% to
40%). These differences in estimates may be attributable to both
the geographical location of the study, the method of diagnosis
used (whether a skin prick test was completed or whether the
diagnosis was based on symptoms), or both (Mims 2014).
Traditionally there has appeared to be a higher prevalence of al-
lergic rhinitis in countries with a ’western lifestyle’ (USA and Eu-
rope), where reported prevalence rates vary between 10%and 30%
(ARIA 2008). For areas outside these regions, Katelaris et al com-
pleted a review of global prevalence studies, which identified a
great diversity in the prevalence estimates of allergic rhinitis both
between and within countries (Katelaris 2012). The review con-
cluded that “the prevalence of allergic rhinitis is increasing and
its adverse impact on the quality of life of affected individuals is
increasingly recognised” (Katelaris 2012). The increase in preva-
lence has been hypothesised as being due to increasing urbanisa-
tion and modification of lifestyles, which has led to reduced expo-
sure to environmental allergens during early childhood resulting
in a weaker immune system and consequent development of aller-
gies, commonly known as the ’hygiene hypothesis’ (ARIA 2008).
There is a well-established link between allergic rhinitis and
asthma. A literature review identified that 40% of allergic rhinitis
patients had asthma (Kim 2008). The proportion of asthmatic
patients reporting symptoms of allergic rhinitis ranged from 30%
to 80%. This connection is perhaps unsurprising as both allergic
rhinitis and asthma are based on shared physiological immune re-
sponses to an identified foreign substance (allergen) (Kim 2008).
Treatment options for allergic rhinitis include allergen avoidance,
pharmacological therapy and immunotherapy. Pharmacological
therapies include various classes of medications, including anti-
histamines, intranasal corticosteroids and anti-leukotrienes (ARIA
2008). Nasal saline has been used as a ’natural’ remedy for cen-
turies and recent Cochrane Reviews have evaluated its efficacy
as a potential treatment or adjunct to pharmacological treatment
for chronic rhinosinusitis and upper respiratory tract infections
(Chong 2016; King 2015).
Description of the intervention
Saline can be deposited in the nasal cavity in various forms, includ-
ing sprays, drops, nebulisers and irrigations. The volume of nasal
saline from sprays and nebulisers can vary greatly. These can be
very low-volume devices (< 5 mL per nostril) through to squeeze
bottles and Neti pots, which are usually high-volume devices (> 60
mL). While nasal saline sprays reach the nasal cavity adequately,
there is some evidence to suggest that high pressure and volume
saline is more effective in penetrating the adjacent sinus cavities
(Wormald 2004).
The saline solutions available are hypotonic (with a concentration
of less than 0.9% NaCl), physiologic (with a concentration of
0.9% NaCl) and hypertonic (with a concentration of greater than
0.9% NaCl). There is some evidence in other conditions that
the tonicity of the saline solution alters its efficacy (Berjis 2011;
Rabago 2005). In addition, the pH of saline solutions has been
investigated and there is some evidence that solutions buffered
with sodiumbicarbonate (increased alkalinity)may have an impact
on the nasal symptoms of patients with allergic rhinitis (Chusakul
2013).
How the intervention might work
The physiological mechanisms underlying any benefit of the use of
nasal saline are not fully understood but it is commonly proposed
that the primary mechanism of action is mechanical (Barham
2015). This may include clearance of mucus (saline thins mucus
and helps to clear it out) (Elkins 2011), and removal of inflamma-
tion mediators such as histamine (Georgitis 1994). There is some
evidence to suggest that at some concentrations nasal saline may
improve ciliary beat function (Bonnomet 2016) and mucociliary
2Saline irrigation for allergic rhinitis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
function (Hermelingmeier 2012). Adverse effects of nasal saline ir-
rigation are thought to be rare and generally mild but may include
ear fullness, stinging of the nasal mucosa and epistaxis (Khianey
2012).
Why it is important to do this review
Allergic rhinitis is a highly prevalent condition with a large impact
on patients and high healthcare costs: both direct, from the cost of
repeat healthcare visits and of chronic medical therapy, and indi-
rect, via absenteeism and lost productivity (Schoenwetter 2004).
Nasal saline potentially represents a safe and inexpensive therapy
for allergic rhinitis. Determining the effects (benefits and poten-
tial harms) has important implications for treatment recommen-
dations.
PreviousCochrane Reviews have demonstrated some possible ben-
efit of saline in patients with chronic rhinosinusitis (Chong 2016)
and upper respiratory tract infections (King 2015). The two most
recent systematic reviews identified on the use of nasal saline in
allergic rhinitis had latest search dates of 2010 (Hermelingmeier
2012) and December 2011 (Khianey 2012). Khianey 2012 lim-
ited their inclusion criteria to studies published in English and also
included studies in populations with a range of different sinonasal
conditions including upper respiratory tract infection and chronic
rhinosinusitis. Hermelingmeier 2012 specified the population as
people with seasonal or perennial allergic rhinitis. This review
looked at prospective trials (including before and after studies)
and only included studies published in English or German. Both
reviews identified potential benefits for patients in terms of symp-
tom improvement and found that saline irrigation was well toler-
ated, but both reviews highlighted the need for further research
in this area in order for definitive conclusions to be drawn. This
review will include recently published studies and we will apply
no restriction with regard to language of publication.
O B J E C T I V E S
To evaluate the effects of nasal saline irrigation in patients with
allergic rhinitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials, and cross-over trials if the data
from the first phase are available;
• patients were followed up for at least two weeks.
We will exclude studies with the following design characteristics:
• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of nasal saline irrigation on surgical
outcomes.
Types of participants
Patients (adults and children) with clinical symptoms character-
istic of allergic rhinitis with a positive radioallergosorbent test
(RAST) or skin prick test (SPT).
We will exclude studies that included amajority (more than 50%)
of participants with:
• non-allergic rhinitis;
• chronic rhinosinusitis;
• acute sinusitis;
• cystic fibrosis;
• immunotherapy started within the prior year;
• any alteration of allergic rhinitis-specific pharmacotherapy
(antihistamines, intranasal corticosteroids, anti-leukotrienes)
during the trial;
• aspirin-exacerbated respiratory disease;
• surgery for turbinate reduction within three months prior
to study.
Where a study includes a mixed group of participants, we will
exclude it if more than 50% of the participants met the ’excluded’
population criteria above, unless the study reports the results for
the different populations separately. Similarly, where more than
50%of the people in the study have allergic rhinitis wewill include
the study but, where possible, we will only use the results for the
population with allergic rhinitis.
Types of interventions
The use of saline, as an active treatment, delivered to the nose by
any means (douche, irrigation, pulsed, spray or nebuliser).
Tonicity: we will include all concentrations of saline. ’Hypotonic’
will be defined as a concentration of less than 0.9% NaCl, ’physi-
ologic’ as 0.9%NaCl and ’hypertonic’ as greater than 0.9%NaCl.
Volume: we will include all volumes of saline treatments. ’Very
low-volume’ will relate tomisting sprays or other deliverymethods
where the volume of application is likely to be less than 5 mL per
nostril per application. ’Low-volume’ will be defined as between 5
mL and 59 mL per nostril per application. ’High-volume’ will be
defined as a volume of 60mL or greater per nostril per application.
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We will include studies investigating ’buffered’ saline solutions
where the aim is to adjust the pH of the solution. We will exclude
studies that used formulations of saline solution that contain other
additives, such as xylitol, antibacterials and surfactants. We will
also exclude studies using other formulations, such as lactated
Ringer’s solution.
There will be no minimum duration of treatment.
Comparisons
The main comparison pairs will be:
• nasal saline versus no treatment/placebo;
• nasal saline plus ’standard treatment’ versus placebo or no
treatment plus ’standard treatment’.
Other possible comparison pairs include:
• nasal saline versus ’standard’ treatment’.
The term ’standard treatment’ refers to commonly accepted treat-
ments such as antihistamines and intranasal corticosteroids, as rec-
ommended by internationally accepted treatment guidelines, such
as the ARIA guidelines (ARIA 2008).
Types of outcome measures
We will analyse the following outcomes in the review, but we will
not use them as a basis for including or excluding studies.
Primary outcomes
• Disease severity, as measured by patient-reported symptom
score (such as the Total Nasal Symptom Score (TNSS)
questionnaire and visual analogue scales (VAS)).
• Significant local adverse effects: epistaxis.
Secondary outcomes
• Disease-specific health-related quality of life, using validated
disease-specific health-related quality of life scores, such as the
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ),
Mini Rhinoconjunctivitis Quality of Life Questionnaire
(MiniRQLQ) and Rhinitis Symptom Utility Index (RSUI).
• Individual symptom scores for the following symptoms:
◦ anterior rhinorrhoea (runny nose): where a study
reports ’rhinorrhoea’ as the outcome, in the absence of a
definition within the paper we will assume that this measures
anterior rhinorrhoea. Where the authors report a combined
outcome for anterior and posterior rhinorrhoea and we are not
able to obtain individual results, we will record this as a
combined ’anterior and posterior rhinorrhoea’ category;
◦ posterior rhinorrhoea (post-nasal drip);
◦ nasal blockage or congestion or obstruction;
◦ nasal itching;
◦ sneezing.
• Generic health-related quality of life, using validated
generic quality of life scores, such as the SF-36, EQ-5D and
other well-validated instruments.
• Any other local adverse effects: local irritation, discomfort.
• Aural symptoms: ear pain, pressure or feeling of fullness.
• Endoscopic score (e.g. Lund-Mackay/Lund-Kennedy).
As both short-term and long-term effects are important we will
evaluate efficacy outcomes at the following time points:
• up to four weeks from the start of treatment (particularly
relevant for intermittent allergic rhinitis);
• from four weeks to six months;
• from six months to 12 months; and
• at more than 12 months (particularly relevant for persistent
allergic rhinitis).
Where a study reports data for an outcome at more than one time
point, we will include the data for the longest of each of the four
time points above. For example, if a study reports outcomes at
one week, three weeks and 12 weeks from the start of treatment,
we will use the three-week results (for the up to four weeks time
point) and the 12-week results (for the four weeks to six months
time point). We will not report the results at one week.Wewill pay
attentionduring the analysis to the preventionof ’double counting’
of studies when presenting summary results.
We will not report data after the treatment has been discontinued
as saline is not expected to have effects that continue past the end
of the treatment duration.
For adverse effects, we will analyse data from the longest time
periods available.
Search methods for identification of studies
The Cochrane ENT Information Specialist will conduct system-
atic searches for randomised controlled trials and controlled clin-
ical trials. There will be no language, publication year or publica-
tion status restrictions. We may contact original authors for clar-
ification and further data if trial reports are unclear and we will
arrange translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• the Cochrane Register of Studies ENT Trials Register
(search to date);
• Cochrane Register of Studies Online (search to date);
• Ovid MEDLINE (1946 to date);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations);
◦ PubMed (as a top up to searches in Ovid MEDLINE);
• Ovid EMBASE (1974 to date);
• Ovid CAB abstracts (1910 to date);
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• Ovid AMED (1985 to date);
• LILACS (search to date);
• KoreaMed (search to date);
• IndMed (search to date);
• PakMediNet (search to date);
• Web of Knowledge, Web of Science (1945 to date);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies to date);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (search to date);
• ISRCTN, www.isrctn.com (search to date);
• Google Scholar (search to date);
• Google (search to date).
The subject strategies for databases will be modelled on the search
strategy designed for CENTRAL (Appendix 1). Where appropri-
ate, these will be combined with subject strategy adaptations of
the highly sensitive search strategy designed by Cochrane for iden-
tifying randomised controlled trials and controlled clinical trials
(as described in the Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011)).
Searching other resources
We will scan the reference lists of identified publications for addi-
tional trials and contact trial authors if necessary. In addition, the
Information Specialist will search Ovid MEDLINE, theCochrane
Library and Google to retrieve existing systematic reviews relevant
to this systematic review, so that we can scan their reference lists
for additional trials.
Data collection and analysis
Selection of studies
At least two review authors (KHandSG)will independently screen
all titles and abstracts of the studies obtained from the database
searches to identify potentially relevant studies. At least two review
authors (KH and CP) will evaluate the full text of each potentially
relevant study to determine whether it meets the inclusion and
exclusion criteria for this review.
We will resolve any differences by discussion and consensus, with
the involvement of a third author for clinical and/methodological
input where necessary.
Data extraction and management
At least two review authors (KH and SG) will independently ex-
tract data from each study using a standardised data collection
form (see Appendix 2).Whenever a study has more than one pub-
lication, we will retrieve all publications to ensure complete extrac-
tion of data.Where there are discrepancies in the data extracted by
different review authors, we will check these against the original
reports and we will resolve differences by discussion and consen-
sus, with the involvement of a third author or a methodologist
where appropriate. We will contact the original study authors for
clarification or for missing data whenever required. If differences
are found between publications of a study, we will contact the
original authors for clarification. We will use data from the main
paper(s) if no further information is found.
We will include key characteristics of the studies, such as study
design, setting, sample size, population and how outcomes were
defined or collected in the studies. In addition, we will also collect
baseline information on prognostic factors or effect modifiers. For
this review, this will include:
• age of participants;
• intermittent or persistent allergic rhinitis;
• type of allergic trigger (e.g. mites, pollens, animals, etc.);
• severity of allergic rhinitis (’mild’ or ’moderate/severe’ as
defined in ARIA 2008).
For the outcomes of interest to the review, we will extract the
findings of the studies on an available case analysis basis; i.e. we
will include data from all patients available at the time points
based on the treatment randomisedwhenever possible, irrespective
of compliance or whether patients had received the treatment as
planned.
In addition to extracting prespecified information about study
characteristics and aspects of methodology relevant to risk of bias,
we will extract the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data are not available, we will extract the values for
change from baseline. We will analyse data from measurement
scales such as RQLQ and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appear to be approximately
normally distributed or if the analysis that the investigators
performed suggested parametric tests were appropriate, then we
will treat the outcome measures as continuous data. Alternatively,
if data are available, we plan to convert into binary data.
We have prespecified the time points of interest for the outcomes
in this review (Types of outcome measures). While studies may
have reported data at multiple time points, we will only extract
the longest available data within the time points of interest. For
example, if a study reports data at one, two and four weeks, we
will only extract and analyse the data for the four-week follow-up.
Extracting data from figures
Where values for primary or secondary outcomes are shown as
figures within the paper we will contact the study authors to try
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to obtain the raw values. When the raw values are not provided,
we will extract information from the graphs using an online data
extraction tool (http://arohatgi.info/WebPlotDigitizer/app/), us-
ing the best quality version of the relevant figures available.
Assessment of risk of bias in included studies
KH and SG will undertake assessment of the risk of bias of the
included trials independently, with the following taken into con-
sideration, as guided by theCochrane Handbook for Systematic Re-
views of Interventions (Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We will use the Cochrane ’Risk of bias’ tool in RevMan 5.3 (
RevMan 2014), which involves describing each of these domains
as reported in the trial and then assigning a judgement about the
adequacy of each entry: ’low’, ’high’ or ’unclear’ risk of bias.
Measures of treatment effect
Wewill summarise the effects of dichotomous outcomes (e.g. pro-
portion of patients with symptom resolution) as risk ratios (RR)
with 95%confidence intervals (CIs). For the key outcomes that we
will present in the ’Summary of findings’ table, we will also express
the results as absolute numbers based on the pooled results and
compared to the assumed risk. We also plan to calculate the num-
ber needed to treat to benefit (NNTB) using the pooled results.
The assumed baseline risk will typically be either (a) the median of
the risks of the control groups in the included studies, this being
used to represent a ’medium risk population’ or, alternatively, (b)
the average risk of the control groups in the included studies used
to represent the ’study population’ (Handbook 2011). If a large
number of studies are available, and where appropriate, we also
plan to present additional data based on the assumed baseline risk
in (c) a low-risk population and (d) a high-risk population.
For continuous outcomes, we will express treatment effects as a
mean difference (MD) with standard deviation (SD). If different
scales are used to measure the same outcome we will use the stan-
dardised mean difference (SMD), and we will provide a clinical
interpretation of the SMD values.
Unit of analysis issues
This review will not use data from phase II of cross-over studies or
from studies where the patient is not the unit of randomisation,
i.e. studies where the side of the nose (right versus left) was ran-
domised.
If we find cluster-randomised trials, we will analyse these according
to the methods in section 16.3.3 of the Cochrane Handbook for
Systematic Reviews of Interventions (Handbook 2011).
Dealing with missing data
We will contact study authors via email whenever the outcome of
interest is not reported if the methods of the study suggest that the
outcome had been measured. We will do the same if not all data
required for meta-analysis are reported, unless the missing data are
standard deviations. If standard deviation data are not available
we will approximate these using the standard estimation methods
from P values, standard errors or 95% CIs if these are reported,
as detailed in the Cochrane Handbook for Systematic Reviews of
Interventions (Handbook 2011).Where it is impossible to estimate
these, we will contact the study authors.
Apart from imputations for missing standard deviations, we will
not conduct any other imputations. We will extract and analyse
data for all outcomes using the available case analysis method.
Assessment of heterogeneity
Wewill assess clinical heterogeneity (whichmay be present even in
the absence of statistical heterogeneity) by examining the included
trials for potential differences between studies in the types of par-
ticipants recruited (including age of participants), interventions
or controls used and the outcomes measured.
We will assess statistical heterogeneity by visually inspecting the
forest plots and by considering the Chi² test (with a significance
level set at P < 0.10) and the I² statistic, which calculates the
percentage of variability that is due to heterogeneity rather than
chance, with I² values over 50% suggesting substantial heterogene-
ity (Handbook 2011).
Assessment of reporting biases
Wewill assess reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We will assess within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this can be obtained. If the protocol is not available, we
will compare the outcomes reported to those listed in the methods
section. If results are mentioned but not reported adequately in a
way that allows analysis (e.g. the report only mentions whether the
results were statistically significant or not), bias in a meta-analysis
is likely to occur. We will try to find further information from the
study authors. If no further information can be obtained, we will
note this as being a ’high’ risk of bias. Where there is insufficient
information to judge the risk of bias we will note this as an ’un-
clear’ risk of bias (Handbook 2011).
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Publication bias (between-study reporting bias)
We plan to create funnel plots if sufficient trials (more than 10)
are available for an outcome. If we observe asymmetry of the fun-
nel plot, we plan to conduct more formal investigation using the
methods proposed by Egger 1997.
Data synthesis
We will conduct all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we plan to analyse treat-
ment differences as a risk ratio (RR) calculated using the Mantel-
Haenszel methods. We plan to analyse time-to-event data using
the generic inverse variance method.
For continuous outcomes, if all the data are from the same scale,
we will pool mean values obtained at follow-up with the change
in outcomes (i.e. difference between pre- versus post-treatment
values) and report this as a MD. However, if the SMD has to be
used as an effect measure, we will not pool change and endpoint
data.
When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
Where data are available, we plan to conduct some subgroup anal-
yses regardless of whether statistical heterogeneity is observed, as
these are widely suspected to be potential effect modifiers. For this
review, this includes the following.
• Volume of saline delivery (e.g. ’very low’, ’low’ and ’high’
volume). There is evidence of a difference in effectiveness
between high- and low-volume saline irrigation in patients with
chronic sinonasal symptoms (Pynnonen 2007).
• Tonicity of saline solution (hypertonic, isotonic and
hypotonic solutions). There is some evidence in other conditions
that tonicity may have an effect on the efficacy of nasal saline
(Berjis 2011; Rabago 2005).
• Alkalinity of saline solution. There is evidence that
increased alkalinity of the saline solution improves some nasal
symptoms (Chusakul 2013).
• Patient age (children, adults or mixed population). There
may be differences in physiology that are unknown and
compliance and volumes may well be quite different in the
paediatric population compared to adults.
We plan to present the main analyses of this review according
to the volume of saline delivery. We intend to present all other
subgroup analysis results in tables.
In addition to the subgroups above, we plan to conduct the follow-
ing subgroup analyses in the presence of statistical heterogeneity:
• method of delivery (e.g. nebuliser, sprays, irrigations);
• duration of treatment;
• frequency of allergic rhinitis symptoms (e.g. intermittent or
persistent as defined by ARIA 2008), where an older study using
the ’seasonal’ and ’perennial’ classification is used, we will
interpret seasonal as ’intermittent’ allergic rhinitis and ’perennial’
as ’persistent’ unless there is specific information in the paper
that would make this inappropriate.
• severity of symptoms (mild, moderate/severe as defined by
ARIA 2008).
When studies have a mixed group of patients, we plan to analyse
the study as one of the subgroups (rather than as a mixed group)
if more than 80% of the participants belong to one category. For
example, if 81% of patients are over 18, we will analyse the study
as though the participants were adults.
Sensitivity analysis
We plan to carry out sensitivity analyses to determine whether
the findings are robust to the decisions made in the course of
identifying, screening and analysing the trials. We plan to conduct
sensitivity analysis for the following factors, whenever possible:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: evaluating the impact of
missing data on the results of the studies due to participant
attrition, to determine whether the missing outcome data for the
participants in the trial could have influenced the results of the
review;
• how outcomes were measured: we plan to investigate the
impact of including data where the validity of the measurement
instrument used was unclear.
If any of these investigations find a difference in the size of the
effect or heterogeneity, we will mention this in the ’Effects of
interventions’ section.
GRADE and ’Summary of findings’ table
Using the GRADE approach, at least two review authors (KH,
SG) will independently rate the overall quality of evidence using
the GDT tool (http://www.guidelinedevelopment.org/) for the
main comparison pairs listed in the Types of interventions section.
The quality of evidence reflects the extent to which we are confi-
dent that an estimate of effect is correct and we will apply this in
the interpretation of results. There are four possible ratings: high,
moderate, low and very low. A rating of high quality of evidence
implies that we are confident in our estimate of effect and that
further research is very unlikely to change our confidence in the
estimate of effect. A rating of very low quality implies that any
estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
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low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We will include a ’Summary of findings’ table, constructed ac-
cording to the recommendations described in Chapter 10 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011). We will include the following outcomes in
the ’Summary of findings’ table: patient-reported disease severity
score, individual symptom scores, significant adverse events (epis-
taxis), disease-specific health-related quality of life and other ad-
verse events (local irritation/discomfort).
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Appendix 1. Search strategies
CRSO MEDLINE (Ovid) Embase (Ovid) Web of Science (Web of
Knowledge)
#1 MESH DESCRIPTOR
Rhinitis
#2 MESH DESCRIPTOR
Conjunctivitis
#3 (rhinit* or Rhinoconjunc-
tivitis or conjunctivitis):TI,AB,
KY
#4 #1 OR #2 OR #3
#5 MESH DESCRIPTOR Al-
lergens EXPLODE ALL
TREES
#6
MESH DESCRIPTOR Pollen
EXPLODE ALL TREES
#7MESHDESCRIPTORHy-
persensitivity EXPLODE ALL
1 Rhinitis/
2 Conjunctivitis/
3 (rhinit* or Rhinoconjunctivi-
tis or conjunctivitis).ab,kf,ti
4 1 or 2 or 3
5 exp Allergens/
6 exp Pollen/
7 exp Hypersensitivity/
8 (allerg* or hypersensitivit* or
perennial or nonseason* or sea-
son* or pollen* or dust or hair*
or dander or mite*).ab,kf,ti
9 5 or 6 or 7
10 4 and 9
11 exp Rhinitis, Allergic/
12 exp Conjunctivitis, Allergic/
1 rhinitis/
2 conjunctivitis/
3 (rhinit* or Rhinoconjunctivi-
tis or conjunctivitis).ab,kw,ti
4 1 or 2 or 3
5 exp allergen/
6 exp pollen/
7 exp hypersensitivity/
8 (allerg* or hypersensitivit* or
perennial or nonseason* or sea-
son* or pollen* or dust or hair*
or dander or mite*).ab,kw,ti
9 5 or 6 or 7 or 8
10 4 and 9
11 exp allergic rhinitis/
12 exp allergic conjunctivitis/
#1 TOPIC:
(rhinit* or Rhinoconjunctivitis
or conjunctivitis)
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#2 TOPIC: (allerg* or hyper-
sensitivit* or perennial or non-
season* or season* or pollen* or
dust or hair* or dander ormite*)
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#3 #2 AND #1
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#4 TOPIC: (hayfever or “hay
fever” or pollenosis or polli-
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(Continued)
TREES
#8 (allerg* or hypersensitivit* or
perennial or nonseason* or sea-
son* or pollen* or dust or hair*
or dander or mite*):TI,AB,KY
#9 #5 OR #6 OR #7 OR #8
#10 #4 AND #9
#11 MESH DESCRIPTOR
Rhinitis, Allergic EXPLODE
ALL TREES
#12 MESH DESCRIPTOR
Conjunctivitis, Allergic EX-
PLODE ALL TREES
#13 (hayfever or “hay fever” or
pollenosis or pollinosis or SAR
or PAR):TI,AB,KY
#14 #10 OR #11 OR #12 OR
#13
#15 MESH DESCRIPTOR
Solutions
#16 MESH DESCRIPTOR
Hypertonic Solutions
#17 MESH DESCRIPTOR
Saline Solution, Hypertonic
EXPLODE ALL TREES
#18 MESH DESCRIPTOR
isotonic solutions EXPLODE
ALL TREES
#19 MESH DESCRIPTOR
Sodium Chloride EXPLODE
ALL TREES
#20 MESH DESCRIPTOR
Mineral Waters EXPLODE
ALL TREES
#21
MESH DESCRIPTOR seawa-
ter EXPLODE ALL TREES
#22 MESH DESCRIP-
TORHypotonic Solutions EX-
PLODE ALL TREES
#23 (saline or “sodium chlo-
ride” or saltwater or hyper-
tonic* or hypotonic* or iso-
tonic* or hypersaline or “seawa-
ter” or seawater or ((salt* or
thermal or mineral or sulfur* or
bromic or iodic* or bromide or
iodine or bromine) and (water*
or solution*))):TI,AB,KY
13 (hayfever or “hay fever” or
pollenosis or pollinosis or SAR
or PAR).ab,kf,ti
14 10 or 11 or 12 or 13
15 Solutions/
16 Hypertonic Solutions/
17 exp Saline Solution, Hyper-
tonic/
18 exp isotonic solutions/
19 exp Sodium Chloride/
20 exp Mineral Waters/
21 exp seawater/
22 exp Hypotonic Solutions/
23 (saline or “sodium chloride”
or saltwater or hypertonic* or
hypotonic* or isotonic* or hy-
persaline or “sea water” or sea-
water or ((salt* or thermal or
mineral or sulfur* or bromic or
iodic* or bromide or iodine or
bromine) and (water* or solu-
tion*))).ab,kf,ti
24 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22 or 23
25 Therapeutic Irrigation/
26 exp Nasal Lavage/
27 exp Administration, Inhala-
tion/
28 exp Administration, In-
tranasal/
29 exp Nasal Sprays/
30 exp Buffers/
31 (douch* or spray* or lavag*
or wash* or rinse* or rinsing or
irrigat* or pulsed or nebulise* or
aerosol* or buffer* or atomis* or
atomiz* or (squeeze and bottle)
).ab,kf,ti
32 (intranasal or inhalation* or
irrigator).ab,kf,ti.
33 25 or 26 or 27 or 28 or 29
or 30 or 31 or 32
34 24 and 33
35 (sterimar or NeilMed or
nasaline or navage or marimer
or physiomer or Emcur or “sim-
ply saline” or “nasal mist” or ayr
or salex or “otrovin saline” or
13 (hayfever or “hay fever” or
pollenosis or pollinosis or SAR
or PAR).ab,kw,ti
14 10 or 11 or 12 or 13
15 “solution and solubility”/
16 exp hypertonic solution/
17 exp sodium chloride/
18 exp isotonic solution/
19 exp mineral water/
20 exp sea water/
21 exp hypotonic solution/
22 (saline or “sodium chloride”
or saltwater or hypertonic* or
hypotonic* or isotonic* or hy-
persaline or “sea water” or sea-
water or ((salt* or thermal or
mineral or sulfur* or bromic or
iodic* or bromide or iodine or
bromine) and (water* or solu-
tion*))).ab,kw,ti
23 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22
24 lavage/
25 exp nasal lavage/
26 exp inhalational drug ad-
ministration/
27 exp intranasal drug admin-
istration/
28 exp nose spray/
29 exp buffer/
30 (douch* or spray* or lavag*
or wash* or rinse* or rinsing or
irrigat* or pulsed or nebulise* or
aerosol* or buffer* or atomis* or
atomiz* or (squeeze and bottle)
).ab,kw,ti
31 (intranasal or inhalation* or
irrigator).ab,kw,ti.
32 24 or 25 or 26 or 27 or 28
or 29 or 30 or 31
33 23 and 32
34 (sterimar or NeilMed or
nasaline or navage or marimer
or physiomer or Emcur or “sim-
ply saline” or “nasal mist” or ayr
or salex or “otrovin saline” or
ISCS or Prorhinel or SSBI).ab,
kw,ti
nosis)
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#5 #4 OR #3
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#6 TOPIC: ((saline or “sodium
chloride” or saltwater or hy-
pertonic* or hypotonic* or iso-
tonic* or hypersaline or “seawa-
ter” or seawater or ((salt* or
thermal or mineral or sulfur* or
bromic or iodic* or bromide or
iodine or bromine) and (water*
or solution*))))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#7 TOPIC: ((douch* or spray*
or lavag* or wash* or rinse*
or rinsing or irrigat* or pulsed
or nebulise* or aerosol* or
buffer* or atomis* or atomiz* or
(squeeze and bottle)))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#8 TOPIC: ((intranasal or in-
halation* or irrigator))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#9 #8 OR #7
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#10 #9 AND #6
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#11 TOPIC: ((sterimar or
NeilMed or nasaline or nav-
age or marimer or physiomer
or Emcur or “simply saline”
or “nasal mist” or ayr or salex
or “otrovin saline” or ISCS or
Prorhinel or SSBI))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#12 TOPIC: ((nasal or in-
tranasal or sinus or nose or
sinonasal) NEAR/3 (irrigation*
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(Continued)
#24 #15 OR #16 OR #17 OR
#18 OR #19 OR #20 OR #21
OR #22 OR #23
#25 MESH DESCRIPTOR
Therapeutic Irrigation
#26 MESH DESCRIPTOR
Nasal Lavage EXPLODE ALL
TREES
#27 MESH DESCRIPTOR
Administration, InhalationEX-
PLODE ALL TREES
#28 MESH DESCRIPTOR
Administration, Intranasal EX-
PLODE ALL TREES
#29 MESH DESCRIPTOR
Nasal Sprays EXPLODE ALL
TREES
#30 MESH DESCRIP-
TOR Buffers EXPLODE ALL
TREES
#31 (douch* or spray* or lavag*
or wash* or rinse* or rinsing or
irrigat* or pulsed or nebulise* or
aerosol* or buffer* or atomis* or
atomiz* or (squeeze and bottle)
):TI,AB,KY
#32 (intranasal or inhalation*
or irrigator):TI,AB,KY
#33 #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32
#34 #24 and #33
#35 (sterimar or NeilMed or
nasaline or navage or marimer
or physiomer or Emcur or “sim-
ply saline” or “nasal mist” or ayr
or salex or “otrovin saline” or
ISCS or Prorhinel or SSBI):TI,
AB,KY
#36 (nasal or intranasal or si-
nus or nose or sinonasal) ADJ3
(irrigation* or rinsing or rinse*
or wash* or lavage or douch* or
hygiene):TI,AB,KY
#37 MESH DESCRIPTOR
Mineral Waters EXPLODE
ALL TREES WITH QUALI-
FIERS TU
#38 #34 or #35 or #36 or #37
#39 #14 and #38
ISCS or Prorhinel or SSBI).ab,
kf,ti
36 ((nasal or intranasal or sinus
or nose or sinonasal) adj3 (irri-
gation* or rinsing or rinse* or
wash* or lavage or douch* or hy-
giene)).ab,kf,ti
37 exp Mineral Waters/tu
[Therapeutic Use]
38 34 or 35 or 36 or 37
39 14 and 38
35 ((nasal or intranasal or sinus
or nose or sinonasal) adj3 (irri-
gation* or rinsing or rinse* or
wash* or lavage or douch* or hy-
giene)).ab,kw,ti
36 33 or 34 or 35
37 14 and 36
or rinsing or rinse* or wash* or
lavage or douch* or hygiene))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#13 #12 OR #11 OR #10
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#14 #13 AND #5
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
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CINAHL (EBSCO) ICTRP ClinicalTrials.gov LILACS
S37 S14 AND S36
S36 S32 OR S33 OR S34 OR
S35
S35 (MH “Mineral Water/
TU”)
S34 TX (nasal or intranasal or
sinus or nose or sinonasal) N3
(irrigation* or rinsing or rinse*
or wash* or lavage or douch* or
hygiene)
S33 TX (sterimar or NeilMed
or nasaline or navage or
marimer or physiomer or Em-
cur or “simply saline” or “nasal
mist” or ayr or salex or “otrovin
saline” or ISCS or Prorhinel or
SSBI)
S32 S23 AND S31
S31 S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30
S30 TX (intranasal or inhala-
tion* or irrigator)
S29 TX (douch* or spray* or
lavag* or wash* or rinse* or rins-
ing or irrigat* or pulsed or neb-
ulise* or aerosol* or buffer* or
atomis* or atomiz* or (squeeze
and bottle))
S28 (MH “Buffers+”)
S27 (MH “Administration, In-
tranasal+”)
S26 (MH “Administration, In-
halation+”)
S25 (MH “Nasal Lavage+”)
S24 (MH “Therapeutic Irriga-
tion”)
S23 S15 OR S16 OR S17 OR
S18 OR S19 OR S20 OR S21
OR S22
S22 TX saline or “sodium chlo-
ride” or saltwater or hyper-
tonic* or hypotonic* or iso-
tonic* or hypersaline or “seawa-
ter” or seawater or ((salt* or
thermal or mineral or sulfur* or
bromic or iodic* or bromide or
rhinit* AND saline OR rhinit*
AND salt AND water
OR hayfever AND saline OR
hayfever AND salt AND water
(rhinitis OR hayfever) AND
(saline OR (salt AND water)) |
Interventional Studies
(TW:rhinit* OR TW:rinit OR
TW:hayfever
OR TW:”hay fever” OR TW:
pollinosis OR TW:pollenosis)
AND (TW:salin* OR TW: wa-
ter* OR TW: Agua*)
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iodine or bromine) and (water*
or solution*))
S21 (MH “Hypotonic Solu-
tions+”)
S20 (MH “Mineral Water”)
S19 (MH “Sodium Chlo-
ride+”)
S18 (MH “isotonic
solutions+”)
S17 (MH “Saline Solution, Hy-
pertonic+”)
S16 (MH “Hypertonic Solu-
tions”)
S15 (MH “Solutions”)
S14 S10 OR S11 OR S12 OR
S13
S13 TX hayfever or “hay fever”
or pollenosis or pollinosis or
SAR or PAR
S12 (MH “Conjunctivitis, Al-
lergic+”)
S11 (MH “Rhinitis, Allergic,
Perennial”) OR (MH “Rhinitis,
Allergic, Seasonal”)
S10 S8 AND S9
S9 S4 OR S5 OR S6 OR S7
S8 S1 OR S2 OR S3
S7 TX allerg* or hypersensi-
tivit* or perennial or nonsea-
son* or season* or pollen* or
dust or hair* or dander ormite*)
S6 (MH “Hypersensitivity+”)
S5 (MH “Pollen+”)
S4 (MH “Allergens+”)
S3 TX rhinit* or Rhinocon-
junctivitis or conjunctivitis
S2 (MH “Conjunctivitis”)
S1 (MH “Rhinitis”)
Appendix 2. Data extraction form
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REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
Flow chart of trial Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ’dropouts’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
1This should be the
therefore not consider
analyses (e.g. because
outcome was not
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Information to go into ’Characteristics of included studies’ table Information to go
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no. of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
• Type of allergic rhinitis: [persistent or intermittent as per
ARIA 2008 guidelines]
• Severity of allergic rhinitis: [mild or moderate/severe as per
ARIA 2008 guidelines]
• Type of allergic trigger: [e.g. mites, pollens, animals, etc.]
• Other important effect modifiers, if applicable: (e.g.
comorbidity of asthma):
Inclusion criteria: [state diagnostic criteria used for allergic rhinitis,
polyps score if available]
Exclusion criteria:
Interventions Intervention (n = x): intervention name including tonicity,
method of administration [including volume], frequency of ad-
ministration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment
arms):
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Disease severity, as measured by patient-reported symptom
score (such as the Total Nasal Symptom Score (TNSS)
questionnaire and visual analogue scales)
• Significant adverse effects: epistaxis
Secondary outcomes:
• Patient-reported individual symptom scores for the
following symptoms:
◦ nasal obstruction/blockage/congestion
◦ nasal discharge (anterior or posterior rhinorrhoea -
identify which one, or if both have been reported)
◦ nasal itching
◦ sneezing
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Rhinoconjunctivitis
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(Continued)
Quality of Life Questionnaire (RQLQ), Mini
Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ)
and Rhinitis Symptom Utility Index (RSUI)
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments
• Other local adverse effects: local irritation/discomfort, aural
symptoms
• Endoscopic score (e.g. Lund-Mackay/Lund-Kennedy)
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: “…”
Comment:
Allocation concealment (selection bias) Quote: “…”
Comment:
Blinding of participants and personnel
(performance bias)
Quote: “…”
Comment:
Blinding of outcome assessment (detection
bias)
Quote: “…”
Comment:
Incomplete outcome data (attrition bias) Quote: “…”
Comment:
Selective reporting (reporting bias) Quote: “…”
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: “…”
Comment:
Other bias (see section 8.15) Quote: “…”
Comment:
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Findings of study: continuous outcomes Findings of study:
Results (continuous data table) Results (continuous
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge (an-
terior or pos-
terior rhinor-
rhoea - specify
which one if it
is known)
(instrument
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(Continued)
name/range)
Sneezing
(instrument
name/range)
Nasal itching
(instrument
name/range)
Endoscopic
score
(instrument
name/range)
Comments: Comments:
Results (dichotomous data table) Results (dichotomous
Outcome Intervention Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Epistaxis/
nosebleed
Nasal saline
Local irritation
(sore throat, oral
thrush, discom-
fort)
Nasal saline
Local adverse ef-
fects: Eustachian
tube dysfunction
Nasal saline
The following adverse effects will only be extracted if the comparison arm is one of the interventions indicated The following adverse
indicated
Os-
teoporosis (min-
imum 6months)
INCS
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(Continued)
Stunted growth
(children, mini-
mum 6 months)
INCS Can also be mea-
sured as average
height
Mood
disturbances
Oral steroids
Gastrointestinal
disturbances (di-
arrhoea, nausea,
vomiting, stom-
ach irritation)
Oral steroids
Antibiotics
Insomnia Oral steroids
Os-
teoporosis (min-
imum 6months)
INCS
Oral steroids
Skin irritation Antibiotics
Anaphy-
laxis or other se-
rious allergic re-
actions such
as Stevens-John-
son syndrome
Antibiotics
An-
tihistamine and
decongestant ad-
verse
events: somno-
lence, irritability,
insomnia, rhini-
tis medicamen-
tosa, prolonged
middle ear effu-
sion
Antihistamines/
decongestants
Comments: Comments:
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